Increased Fracture Risk in Women Treated with Aromatase Inhibitors versus Tamoxifen: Beneficial Effect of Bisphosphonates
In conclusion, fracture risk in postmenopausal women during aromatase inhibitor treatment, in real ‐life conditions, was>40% compared to tamoxifen, corroborating previous randomized controlled trials results. In high ‐risk patients, bisphosphonate users had lower significant fracture incidence during aromatase inhibitor therapy than non‐bisphosphonate‐users. Monitoring fracture risk and related risk factors in aromatase inhibitor patients is advisable.This article is protected by copyright. All rights reserved.
Source: Journal of Bone and Mineral Research - Category: Orthopaedics Authors: Marta Pineda ‐Moncusí,
Natalia Garcia‐Giralt,
Adolfo Diez‐Perez,
Sonia Servitja,
Ignasi Tusquets,
Daniel Prieto‐Alhambra,
Xavier Nogués Tags: Original Article Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Oral Cancer | Orthopaedics | Osteoporosis | Primary Care | Study | Tamoxifen | Women